Background: PFA-100™ is a point-of-care assay that evaluates platelet reactivity in high-
shear-stress conditions by measuring the closure time (CT) of a membrane aperture. When …

It was the aim of the present study to perform a systematic review of the published studies
that estimated the prevalence of non-responders to aspirin, as assessed by the closure time …

BACKGROUND: Recently, a growing body of evidence on the possible role of residual
platelet reactivity (RPR) in affecting clinical events has accumulated. The aim of this study …

Cardiovascular diseases remain the leading global cause of mortality indicating the need to
identify all possible factors reducing primary and secondary risk. This study screened the in …

Background: Genetic C3435T polymorphism of the multidrug resistance gene-1 (MDR-1)
limits oral bioavailability of clopidogrel and influences prognosis in patients with myocardial …

Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to
prevent recurrent ischemic event occurrence in coronary artery disease patients. Generally …

Background The use of aspirin is well established for secondary prevention of
cardiovascular disease. However, a proportion of patients suffer repeat cardiovascular …

Novel P2Y12 ADP receptor blockers (ADPRB) should be preferred in dual-antiplatelet
therapy in patients with acute coronary syndrome. Nevertheless, there are still patients who …

Enhanced platelet activity correlates with early markers of myocardial damage in patients
with cardiovascular disease. However, the extent to which enhanced platelet function …

Conclusion: Analyzing the data of different laboratory methods aspirin resistance seems to
be associated with poor clinical outcome, although currently no standardized or widely …